The user experienced side effects from various hair loss treatments, including RU58841, finasteride, and dutasteride. They are uncertain about what treatment to try next.
Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.
Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.
The user is considering switching from finasteride and RU58841 to dutasteride due to ongoing hair loss concerns. They are unsure if the hair loss is due to shedding or worsening condition.
The conversation discusses hair regrowth results after using finasteride, minoxidil, and dermarolling for four months. Users inquire about dosages and when results were first noticed.
RU58841, combined with Dutasteride and topical Minoxidil, is helping users slow hair loss. Long-term users report positive results without significant side effects.
The user experienced eyebrow hair loss after COVID-19 and has not seen regrowth despite using Latisse. They are seeking new treatment options but are cautious about spending money on ineffective solutions.
The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.
Alfatradiol is considered safe but less effective than finasteride for hair loss. One user reported subtle regrowth using alfatradiol with finasteride and minoxidil, while another found alfatradiol ineffective.
The user has been using finasteride and minoxidil for 5 years to prevent hair loss and is considering adding dutasteride for regrowth or opting for a hair transplant. Suggestions include trying dutasteride, oral minoxidil, microneedling, and possibly a hair transplant for better results.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
A woman with hair loss discovered she has thyroid cancer, which was found during an MRI and confirmed with an ultrasound. She advises others with symptoms to see a doctor and shares that her cancer was detected after her dog sniffed her neck and she experienced neck pain.
A 27-year-old man shared his hormonal panel results after one year of taking finasteride 1mg/day for hair loss, showing his DHT levels nearly doubled. He reported stabilized hair loss with mild side effects that resolved, and he is considering a hair transplant but is concerned about the increased DHT levels and potential treatment options.
The conversation is about someone's positive results after one month using RU58841 and minoxidil 5% once a day for hair loss. RU58841 is a topical solution that prevents DHT hormone from binding to hair follicles.
The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
The post discusses using a combination of Dutasteride, Minoxidil, Ketoconazole, Estradiol, and Spironolactone for hair regrowth. Users suggest it needs more time and possibly a transplant, with some sharing personal experiences and side effects of similar treatments.
User experienced side effects from oral finasteride and tried topical Alfatradiol for hair loss. Alfatradiol provided maintenance without significant regrowth, and user suggests it as an alternative for those struggling with finasteride side effects.
A user reported a 50% increase in testosterone after 18 months of taking dutasteride for hair loss. The conversation includes skepticism about the reliability of single testosterone tests and questions about estrogen levels.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.
A 20-year-old male is unsure how to interpret his bloodwork results and whether he should take finasteride for hair loss. His bloodwork shows borderline high levels of albumin and testosterone, and high progesterone, but normal levels of other hormones.
A user with kidney disease and high blood pressure experienced hair thinning, especially around the vertex. They are currently using finasteride and oral minoxidil but are considering whether to resume blood pressure medication despite managing symptoms with diet and exercise.
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
Red light therapy for hair loss is controversial, with mixed results reported. Its effectiveness may depend on device quality and proper wavelength, and it is often used with minoxidil and finasteride.
AHK and GHK are discussed for hair growth in the crown area, with questions about side effects and safety after microneedling. Users share experiences and concerns about these treatments.
Ibrox1972 shared an 8.5-month update on their 2,689-graft hair transplant by Dr. Raghu Reddy in London, along with using oral finasteride, oral minoxidil, and microneedling. Users praised the natural-looking results and discussed the importance of choosing a skilled doctor.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.